Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with early idiopathic PD. If tremor is not present, subjects must have unilateral onset and persistent asymmetry of the symptoms.~* Be over 30 years old at the time of diagnosis of PD.~* Hoehn \& Yahr stage is less than or equal to 2.5.~* Currently not receiving dopaminergic therapy and not projected to require dopaminergic therapy for at least 6 months from enrollment.~* Use of MAO-B inhibitors (rasagiline, selegiline), amantadine, or anticholinergics will be allowed. The dosage has to be stable for 3 months prior to baseline visit and throughout the duration of the study.~Exclusion Criteria:~* Subjects with a diagnosis of an atypical Parkinsonism~* Subjects unwilling or unable to give informed consent~* Use of CoQ10 at a dosage \>600mg daily or use of creatine \>5 grams daily within the 60 days prior to randomization~* Exposure to dopaminergic PD therapy within 60 days prior to enrollment or for 3 months or more at any point in the past~* History of clinically significant orthostatic hypotension or presence of orthostatic hypotension at the screening visit defined as \> 20 mmHg change in systolic BP and \>10mm change in diastolic BP after 2 min of standing, or baseline BP \<90/60~* History of congestive heart failure~* History of bradycardia defined as heart rate \<55~* Presence of 2nd or 3rd degree atrioventricular block or other significant ECG abnormalities that in the investigator's opinion would compromise participation in study~* Clinically significant abnormalities in the Screening Visit laboratory studies or electrocardiogram.~* Presence of other known medical or psychiatric comorbidity that in the investigator's opinion would compromise participation in the study~* Prior exposure to isradipine or other calcium channel blockers within 6 months of baseline~* Subjects with history of hypertension treated with a maximum of 2 other antihypertensive agents will be allowed provided that the doses of concomitant anti HTN therapy can be reduced/adjusted during the study based on the BP readings in consultation with the subject's primary care physician or cardiologist.~* Use of grapefruit juice, Ginkgo biloba, St. John's wart and/or ginseng will be prohibited during the study (as they interfere with the metabolism of isradipine).~* Presence of cognitive dysfunction defined by a Mini Mental Status Exam ( MMSE) score \< 26 at screening~* Subjects with clinically significant depression as determined by a Beck Depression Inventory (BDI) score \>15 at screening~* History of exposure to typical or atypical antipsychotics or other dopamine blocking agents within 6 months prior to enrollment~* Subjects have to be on a stable regimen of central nervous system acting medications (benzodiazepines, antidepressants, hypnotics) for 30 days prior to enrollment~* Lactating women or women of childbearing potential who are not surgically sterilized have to use a reliable measure of contraception and have a negative serum pregnancy test at screening~* Participation in other investigational drug trials within 30 days prior to screening~* History of brain surgery for PD

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Isradipine CR 5mg (Type: ACTIVE_COMPARATOR): Isradipine CR 5mg/day
- Isradipine CR 10mg (Type: ACTIVE_COMPARATOR): Isradipine CR 10mg/day
- Isradipine CR 20mg (Type: ACTIVE_COMPARATOR): Isradipine CR 20mg/day
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).